April 1, 1994Open Access
View Full PaperDose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators.
Key Points
- This research aims to evaluate the dose-response relationship of chronic beta-blocker treatment with bucindolol in heart failure patients.
- Investigated the effects of chronic beta-blocker therapy using bucindolol.
Structured PICO
Does chronic beta-blocker treatment with bucindolol improve left ventricular function in patients with heart failure from systolic dysfunction?
P
Population
Patients with heart failure from systolic dysfunction (idiopathic dilated or ischemic cardiomyopathy)
I
Intervention
Bucindolol (chronic beta-blocker treatment)
O
Outcome
Left ventricular functionsurrogate
Bucindolol provides a dose-dependent improvement in left ventricular function in patients with heart failure due to systolic dysfunction.
Abstract
In heart failure from systolic dysfunction, beta-blockade with bucindolol produces a dose-related improvement in and prevents deterioration of left ventricular function.